News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Advanced Vision Therapies, Inc. Awarded Three Phase I SBIRs From NIH To Develop Therapies For Sight-Threatening Eye Diseases


10/19/2005 5:11:14 PM

Advanced Vision Therapies, Inc. (AVT) a biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of major sight-threatening eye diseases, announced today that the National Institutes of Health (NIH) have awarded three independent Small Business Innovative Research (SBIR) grants totaling $687,000. This support will advance AVT's proprietary gene transfer technology toward clinical application for the treatment of prevalent eye diseases including age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES